ArticleTrends in cancer2019
Inhibiting Tumor Fibrosis and Actomyosin through GPCR activation.
Article in Trends in cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review.Cancer biology & medicine · 2024Pooled it
- G Protein-Coupled Estrogen Receptor Regulates Mesenchymal Stem Cell Mechanotransduction and Differentiation.Cellular and molecular bioengineering · 2025Article
- Fibrosis: cross-organ biology and pathways to development of innovative drugs.Nature reviews. Drug discovery · 2025Review
- Fibroblast and myofibroblast activation in normal tissue repair and fibrosis.Nature reviews. Molecular cell biology · 2024Review
- The Role of Myofibroblasts in Physiological and Pathological Tissue Repair.Cold Spring Harbor perspectives in biology · 2023Review
- Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction.Cells · 2021Review
- Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy.Frontiers in immunology · 2021Review
- Mechanotransduction in Wound Healing and Fibrosis.Journal of clinical medicine · 2020Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Myofibroblasts produce desmoplastic stroma around tumors and have emerged as therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) and other cancers. Differentiation of pancreatic stellate cells (PSCs) into myofibroblasts is inhibited by the estrogen-receptor modulator, tamoxifen, which activates a G-protein-coupled receptor (GPCR) for estrogen (GPER). This negatively regulates actomyosin contractility and downstream mechanosensitive signaling to profoundly alter the tumor microenvironment, which appears less fibrotic, less immunosuppressive, and more vascularized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.